EyePoint Pharmaceuticals Stock

EyePoint Pharmaceuticals Dividend 2024

EyePoint Pharmaceuticals Dividend

0 USD

EyePoint Pharmaceuticals Dividend yield

Ticker

EYPT

ISIN

US30233G2093

WKN

A2QJRU

How much dividend does EyePoint Pharmaceuticals 2024 pay?

According to the latest status from August 2024, EyePoint Pharmaceuticals paid a total of 0 USD per share in dividends within the last 12 months. With the current EyePoint Pharmaceuticals price of 9.19 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical EyePoint Pharmaceuticals Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the EyePoint Pharmaceuticals Dividend Safe?

EyePoint Pharmaceuticals has been increasing the dividend for 0 years.

Over the past 10 years, EyePoint Pharmaceuticals has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding EyePoint Pharmaceuticals's Dividend Distributions

EyePoint Pharmaceuticals’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining EyePoint Pharmaceuticals's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

EyePoint Pharmaceuticals's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in EyePoint Pharmaceuticals’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

EyePoint Pharmaceuticals Aktienanalyse

What does EyePoint Pharmaceuticals do?

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint Pharmaceuticals is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about EyePoint Pharmaceuticals stock

How much dividend does EyePoint Pharmaceuticals pay?

Over the past 12 months, EyePoint Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyePoint Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EyePoint Pharmaceuticals?

The current dividend yield of EyePoint Pharmaceuticals is .

When does EyePoint Pharmaceuticals pay dividends?

EyePoint Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EyePoint Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyePoint Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyePoint Pharmaceuticals from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did EyePoint Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of EyePoint Pharmaceuticals in the year 2023?

In the year 2023, EyePoint Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyePoint Pharmaceuticals pay out the dividend?

The dividends of EyePoint Pharmaceuticals are distributed in USD.

Andere Kennzahlen von EyePoint Pharmaceuticals

Our stock analysis for EyePoint Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.